Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke or transient ischemic attack within  year prior to first dose, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect); loss of consciousness within  months may be permitted upon discussion with study principle investigator (PI)
History of any of the following:\r\n* Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within  year to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)\r\n* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial within  months prior to randomization\r\n* Venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks) within  months prior to randomization\r\n* Clinically significant ventricular arrhythmias within  months prior to randomization
History of seizure or condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within  year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
History of any of the following:\r\n* Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within  year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)\r\n* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within  months prior to randomization\r\n* Any condition that in the opinion of the investigator, would preclude participation in this study
History of seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke or, loss of consciousness within  year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
History of any of the following:\r\n* Seizure or known condition that may predispose to seizure (e.g., prior stroke within  year of randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)\r\n* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within  months prior to randomization
History of any of the following:\r\n* Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within  months of cycle  day , brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy)\r\n* Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within  months prior to first dose of study drug; venous thrombotic events within  months are permitted IF they are not attributed to prostate cancer (in the opinion of the treating physician)
Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within  year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
History of seizure or any condition or concurrent medication that may predispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within one year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)